General
Preferred name
GEMFIBROZIL
Synonyms
CI-719 ()
Jezil ()
Decrelip ()
Lopid ()
Gemfibrozil (Lopid) ()
GEMFIBROZIL25812-30-0 ()
NSC-757024 ()
Emfib ()
Gemfibrozilo ()
Gemfibrozil-d6 ()
P&D ID
PD002321
CAS
25812-30-0
114413-98-8
1184986-45-5
Tags
available
drug
Approved by
FDA
First approval
1981
Drug indication
Hyperlipidaemia
Coronary artery disease
Drug Status
approved
Max Phase
4.0
Structure
Probe scores
P&D probe-likeness score
[[ v.score ]]%
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
MOA Gemfibrozil activates peroxisome proliferator-activated receptor alpha (PPARα) transcription factor ligand. This receptor is involved in the metabolism of carbohydrates and fats, as well as the differentiation of adipose tissue. Activation of this receptor increases extrahepatic lipoprotein lipase, and therefore lipoprotein triglyceride lipolysis. This increases the clearance of triglycerides. Increase triglyceride clearance leads to degradation of chylomicrons, VLDL conversion to LDL, LDL conversion to HDL, and increase secretion of lipids into bile in the intestine. Gemfibrozil also inhibits synthesis and increases clearance of apolipoprotein B which carries VLDL.
DESCRIPTION Gemfibrozil is a fibric acid antilipemic agent, pharmacologically similar to clofibrate. (GtoPdb)
DESCRIPTION Gemfibrozil is an activator of PPAR-¦Á, used as a lipid-lowering agent; Gemfibrozil is also a nonselective inhibitor of several P450 isoforms, with Ki values for CYP2C9, 2C19, 2C8, and 1A2 of 5.8, 24, 69, and 82 ¦ÌM, respectively.
PRICE 29
DESCRIPTION Gemfibrozil is the generic name for an oral drug used to lower lipid levels. It belongs to a group of drugs known as fibrates. It is most commonly sold as the brand name, Lopid. Other brand names include Jezil and Gen-Fibro. (BOC Sciences Bioactive Compounds)
DESCRIPTION Gemfibrozil is used as a lipid-lowering drug. It is an activator of alfa-Peroxisome proliferator-activated receptor. Gemfibrozil is also a nonselective inhibitor of Aldose reductase and P450 isoforms CYP2C9, 2C19 and 2C8. Gemfibrozil is indicated to treat patients with Types IV and V hyperlipidemia who have elevated serum triglycerides, elevated VLDL cholesterol, fasting chylomicrons, are at risk of developing pancreatitis, and do not adequately respond to dietary restrictions. (Enamine Bioactive Compounds)
DESCRIPTION Gemfibrozil (CI-719) interacts with peroxisome proliferator-activated receptors (PPARalpha) resulting in PPARalpha-mediated stimulation of fatty acid oxidation and an increase in lipoprotein lipase (LPL) synthesis. Gemfibrozil is a fibric acid derivative with hypolipidemic effects. This enhances triglyceride-rich lipoprotein clearance and reduces the expression of apolipoprotein C-III (apoC-III). The reduction in hepatic production of apoC-III result in the subsequent reduction of serum levels of very-low-density-lipoprotein cholesterol (VLDL-C). In addition, gemfibrozil-mediated PPARalpha stimulation of apoA-I and apoA-II expression results in an increase in high-density lipoprotein cholesterol (HDL-C). (TargetMol Bioactive Compound Library)
Cell lines
0
Organisms
2
Compound Sets
35
AdooQ Bioactive Compound Library
A10424
BOC Sciences Bioactive Compounds
gemfibrozil-cas-25812-30-0-item-84-88721
Cayman Chemical Bioactives
14835
31915
ChEMBL Approved Drugs
CHEMBL457
ChEMBL Drugs
CHEMBL457
Concise Guide to Pharmacology 2017/18
3439
Concise Guide to Pharmacology 2019/20
3439
Concise Guide to Pharmacology 2021/22
3439
Concise Guide to Pharmacology 2023/24
3439
CZ-OPENSCREEN Bioactive Library
Drug Repurposing Hub
DrugBank
DB01241
DrugBank Approved Drugs
DB01241
DrugCentral
1285
DrugCentral Approved Drugs
1285
DrugMAP
DMD8Q3J
DrugMAP Approved Drugs
DMD8Q3J
DrugMatrix
Enamine Bioactive Compounds
EBC-06088
Enamine BioReference Compounds
EU-OPENSCREEN Bioactive Compound Library
EOS101169
Guide to Pharmacology
3439
Mcule NIBR MoA Box Subset
MCULE-4563546953
MedChem Express Bioactive Compound Library
HY-B0258
NCATS Inxight Approved Drugs
Q8X02027X3
NIH Clinical Collections (NCC)
Novartis Chemogenetic Library (NIBR MoA Box)
NPC Screening Collection
NURSA ligand set
nursa/index.jsf?doi=10.1621%2F78D22792E0
Prestwick Chemical Library
ReFrame library
Selleckchem Bioactive Compound Library
Gemfibrozil(Lopid)
TargetMol Bioactive Compound Library
T1415
The Spectrum Collection
ZINC Tool Compounds
ZINC000001530641
External IDs
48
Properties
(calculated by RDKit )
Molecular Weight
250.16
Hydrogen Bond Acceptors
2
Hydrogen Bond Donors
1
Rotatable Bonds
6
Ring Count
1
Aromatic Ring Count
1
cLogP
3.57
TPSA
46.53
Fraction CSP3
0.53
Chiral centers
0.0
Largest ring
6.0
QED
0.78
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
Target
CYP1A2
CYP2C9
Cytochrome P450
PPAR
PPARα
LPL, PPARA, SLCO1B1, SLCO1B3, SLCO2B1
Member status
member
MOA
PPARalpha Agonists
lipoprotein lipase activator
Indication
hyperlipidemia, coronary heart disease
Disease Area
endocrinology, cardiology
Pathway
DNA Damage/DNA Repair
GPCR/G protein
Metabolism
Neuroscience
Cell Cycle/DNA Damage
Metabolic Enzyme/Protease
Vitamin D Related/Nuclear Receptor
Therapeutic Class
Antilipemic Agents
Source data